Inizio Ignite Sparks a New Era of Connected Advisory Solutions
January 7, 2026 | Inizio Ignite
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM to address the growing complexity of today’s pharmaceutical environment. Purpose-built and AI-enabled, Inizio Ignite helps clients shape strategy, drive scalable transformation, and deliver measurable impact uniting connected expertise and advanced technology platforms into a single advisory solution designed to deliver greater impact for clients and the patients they serve.
Inizio Ignite operates as part of Inizio’s broader global commercialization platform, enabling clients to seamlessly access deep, cross-functional expertise across the entire product lifecycle. With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics, and technology capabilities to help clients solve complex challenges in a flexible, client-centred way – from strategy through execution.
Focused exclusively on life sciences and healthcare, Inizio Ignite integrates Inizio’s former Advisory capabilities to create one of the largest and most specialized advisory partners in the sector. With more than 1,000 experts, including 100 PhD, PharmD, and MDs across more than 50 countries, Inizio Ignite advises clients across more than 20 therapy and disease areas and has partnered on 1,100 assets with all top 20 pharmaceutical companies. Across the product lifecycle, from early development through post-launch, Inizio Ignite supports data-driven portfolio and launch strategies, embeds advanced analytics, and translates insight into execution – delivering Intelligent Commercialization™ as part of Inizio’s end-to-end platform.
Remco op den Kelder, Global President of Inizio Ignite, said:
“By uniting our teams, we’re creating something new – an integrated partner bringing together the insight, strategy, and transformation support that pharma companies need to win in today’s market. This evolution represents a meaningful shift in how we serve our clients, delivering clearer answers, stronger guidance, and faster impact for the patients who rely on them.”
“With a seamlessly connected team, clients benefit from deeper expertise and broader capabilities at every stage of their journey. This transformation strengthens our ability to drive innovation at scale, pairing clarity and precision with the speed required to turn strategy into real-world impact. It positions us to advance the next generation of treatments and to help shape the future of human health.”
Find out more about Inizio Ignite and its solutions here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
20 questions: Round 2
As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What do you love about your job?"Watch the video: http://bit.ly/2qA1oP9
Taking an integrated approach to research
Director Melinda Shorr and Associate Director Steven Helm discuss the benefits of integrated research techniques.Watch the video: http://bit.ly/2qF0qO2
Online Community Research
What to consider when running an online research community?
Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch
Helen Parfitt has joined Research Partnership as Head of Therapy Watch at the company’s global head office in London. Therapy Watch is a ‘real-time’ syndicated global market tracking tool that...
Research Partnership is expanding its US capabilities with new offices opening in San Francisco and New York
Research Partnership is today expanding its US operations across both the West and East Coast. Director Tom Winter has relocated from London and is today opening a new office in...
A safe place to talk about Crohn’s
Published in eyeforpharma April 2017 by Mariel Metcalfe
Patient Assistance Programme Evaluation for Cardiovascular Conditions
Our client had launched a self-injection treatment for cardiovascular conditions and were creating an accompanying Patient Assistance Programme (PAP) to educate patients in the use and uptake of this product.Read the case...
What next for the treatment of Psoriasis in Europe?
Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.
20 questions: Round 1
As it's our 20th year anniversary, we invited our employees to play 20 questions - this month "What's the biggest challenge you've overcome at Research Partnership?"Watch the video: https://www.researchpartnership.com/news/2017/03/20-questions-round-1/
Brand tracking research
A common challenge for brand tracking is ensuring the research programme stays relevant to the brand’s current environment. In this video Quantitative Research Directors Karen Swords and Vicky McLellan outline...